{
    "root": "314433f7-d500-d878-e063-6394a90adb5b",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": {
        "text": "Bupropion Hydrochloride",
        "suffix": {
            "text": "(XL)"
        }
    },
    "value": "20250326",
    "ingredients": [
        {
            "name": "HYPROMELLOSE 2910 (15 MPA.S)",
            "code": "36SFW2JZ0W"
        },
        {
            "name": "GLYCERYL DIBEHENATE",
            "code": "R8WTH25YS2"
        },
        {
            "name": "HYDROXYPROPYL CELLULOSE, UNSPECIFIED",
            "code": "9XZ8H6N6OH"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "ETHYLCELLULOSE (100 MPA.S)",
            "code": "47MLB0F1MV"
        },
        {
            "name": "POVIDONE, UNSPECIFIED",
            "code": "FZ989GH94E"
        },
        {
            "name": "METHACRYLIC ACID - ETHYL ACRYLATE COPOLYMER (1:1) TYPE A",
            "code": "NX76LV5T8J"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "FERROSOFERRIC OXIDE",
            "code": "XM0M87F357"
        },
        {
            "name": "PROPYLENE GLYCOL",
            "code": "6DC9Q167V3"
        },
        {
            "name": "BUPROPION HYDROCHLORIDE",
            "code": "ZG7E5POY8O"
        }
    ],
    "indications": "bupropion hydrochloride extended-release tablets ( xl ) aminoketone antidepressant , indicated : • treatment major depressive disorder ( mdd ) ( 1.1 ) • prevention seasonal affective disorder ( sad ) ( 1.2 )",
    "contraindications": "general : • increase dose gradually reduce seizure risk . ( 2.1 , 5.3 ) • periodically reassess dose need maintenance treatment . ( 2.2 ) major depressive disorder • starting dose : 150 mg/day daily . usual target dose : 300 mg daily ( 2.2 ) • 4 days , may increase dose 300 mg daily . ( 2.2 ) seasonal affective disorder • initiative treatment autumn prior onset seasonal depressive symptoms . ( 2.3 ) • starting dose : 150 mg daily . usual target dose : 300 mg daily . ( 2.3 ) • one week , may increase dose 300 mg daily . ( 2.3 ) • continue treatment winter season . ( 2.3 ) hepatic impairment • moderate severe hepatic impairment : 150 mg every day ( 2.6 ) • mild hepatic impairment : consider reducing dose and/or frequency dosing . ( 2.6 , 8.7 ) renal impairment • consider reducing dose and/or frequency dosing . ( 2.7 , 8.6 )",
    "warningsAndPrecautions": "bupropion hydrochloride extended-release tablets usp ( xl ) extended-release tablets supplied : round , white film coated tablets , printed t102 one side plain side . ndc 72789-112-90 bottles 90 store 25°c ( 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] . protect light . bupropion hydrochloride extended-release tablets ( xl ) may odor .",
    "adverseReactions": "bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients seizure disorder . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients current prior diagnosis bulimia anorexia nervosa higher incidence seizures observed patients treated bupropion hydrochloride extended-release tablets ( xl ) [ ( 5.3 ) ] . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients undergoing abrupt discontinuation alcohol , benzodiazepines , barbiturates , antiepileptic drugs [ ( 5.3 ) ( 7.3 ) ] . maois ( intended treat psychiatric disorders ) concomitantly bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment bupropion hydrochloride extended-release tablets ( xl ) contraindicated . increased risk hypertensive bupropion hydrochloride extended-release tablets ( xl ) used concomitantly maois . bupropion hydrochloride extended-release tablets ( xl ) within 14 days discontinuing treatment maoi also contraindicated . starting bupropion hydrochloride extended-release tablets ( xl ) patient treated reversible maois linezolid intravenous methylene blue contraindicated . [ ( 2.9 ) , ( 5.4 ) ( 7.6 ) ] . bupropion hydrochloride extended-release tablets ( xl ) contraindicated patients known hypersensitivity bupropion ingredients bupropion hydrochloride extended-release tablets ( xl ) . anaphylactoid/anaphylactic stevens-johnson syndrome reported [ ( 5.8 ) ] .",
    "indications_original": "Bupropion hydrochloride extended-release tablets (XL) are an aminoketone antidepressant, indicated for: • treatment of major depressive disorder (MDD) ( 1.1 ) • prevention of seasonal affective disorder (SAD) ( 1.2 )",
    "contraindications_original": "General : • Increase dose gradually to reduce seizure risk. ( 2.1 , 5.3 ) • Periodically reassess the dose and need for maintenance treatment. ( 2.2 ) Major Depressive Disorder • Starting dose: 150 mg/day once daily. Usual target dose: 300 mg once daily ( 2.2 ) • After 4 days, may increase the dose to 300 mg once daily. ( 2.2 ) Seasonal Affective Disorder • Initiative treatment in the autumn prior to onset of seasonal depressive symptoms. ( 2.3 ) • Starting dose: 150 mg once daily. Usual target dose: 300 mg once daily. ( 2.3 ) • After one week, may increase the dose to 300 mg once daily. ( 2.3 ) • Continue treatment through the winter season. ( 2.3 ) Hepatic Impairment • Moderate to severe hepatic impairment: 150 mg every other day ( 2.6 ) • Mild hepatic impairment: Consider reducing the dose and/or frequency of dosing. ( 2.6 , 8.7 ) Renal Impairment • Consider reducing the dose and/or frequency of dosing. ( 2.7, 8.6 )",
    "warningsAndPrecautions_original": "Bupropion hydrochloride extended-release tablets USP (XL) extended-release tablets are supplied as:\n                  Round, white film coated tablets, printed with T102 on one side and plain on the other side.\n                  NDC 72789-112-90 Bottles of 90\n                  \n                     Store at 25°C (77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. \n     Protect from light.\n  \n                       Bupropion hydrochloride extended-release tablets (XL) may have an odor.",
    "adverseReactions_original": "Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with seizure disorder.\n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with a current or prior diagnosis of bulimia or anorexia nervosa as a higher incidence of seizures was observed in such patients treated with bupropion hydrochloride extended-release tablets (XL) [\n  \n   see\n   \n    Warnings and Precautions (5.3)\n                        ].\n \n  \n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients undergoing abrupt discontinuation of alcohol, benzodiazepines, barbiturates, and antiepileptic drugs [\n  \n   see\n   \n    Warnings and Precautions (5.3)and\n   \n    Drug Interactions (7.3)\n                        ].\n \n  \n                     The use of MAOIs (intended to treat psychiatric disorders) concomitantly with bupropion hydrochloride extended-release tablets (XL) or within 14 days of discontinuing treatment with bupropion hydrochloride extended-release tablets (XL) are contraindicated. There is an increased risk of hypertensive reactions when bupropion hydrochloride extended-release tablets (XL) are used concomitantly with MAOIs. The use of bupropion hydrochloride extended-release tablets (XL) within 14 days of discontinuing treatment with an MAOI is also contraindicated. Starting bupropion hydrochloride extended-release tablets (XL) in a patient treated with reversible MAOIs such as linezolid or intravenous methylene blue is contraindicated. [\n  \n   see\n   \n    Dosage and Administration (2.9),\n   \n    Warnings and Precautions (5.4)and\n   \n    Drug Interactions (7.6)\n                        ].\n \n  \n                     Bupropion hydrochloride extended-release tablets (XL) are contraindicated in patients with known hypersensitivity to bupropion or other ingredients of bupropion hydrochloride extended-release tablets (XL). Anaphylactoid/anaphylactic reactions and Stevens-Johnson Syndrome have been reported [\n  \n   see\n   \n    Warnings and Precautions (5.8)\n                        ]."
}